SMAD2 and hyperuricemia: In particular, hyperuricemia contributes to MI progression by decreasing fibroblast-derived lumican levels to activate the TGFβ/Smad2/3 signaling pathway, subsequently promoting fibroblast transition to myofibroblasts and enhancing adverse cardiac remodeling.